老年住院患者药物相关再入院预测工具的外部验证与更新
本研究利用瑞典MedBridge试验队列(2516例≥65岁住院患者)对OPERAM药物相关再入院(DRA)预测模型进行外部验证。原始模型区分度中等(C统计量0.62,95%CI 0.59-0.64),校准显示风险低估;更新模型移除「肝硬化伴门脉高压」并加入「多重用药」后,C统计量提升至0.64(95%CI 0.59-0.70),校准改善。更新后的OPERAM DRA预测模型可能有助于临床估计出院后DRA风险。
要点
- 验证队列中23.1%(582/2516)的老年住院患者发生1年内药物相关再入院。
- 原始模型区分度中等(C统计量0.62),校准显示风险被低估。
- 更新模型加入多重用药、移除肝硬化伴门脉高压后区分度略提升至0.64。
核心结论
- 更新后的OPERAM DRA预测模型可用于估计老年住院患者出院后药物相关再入院风险。
- 更新模型区分度仍为中等(C统计量0.64,95%CI 0.59-0.70),校准改善。
研究设计与样本
- 外部验证与模型更新研究,验证队列为瑞典MedBridge多中心整群随机交叉试验队列。
- 验证队列共纳入2516例年龄≥65岁的住院患者。
主要发现
- 验证队列中582例(23.1%)在1年内发生药物相关再入院。
- 原始模型总体准确度良好(缩放Brier评分0.03),但区分度中等(C统计量0.62,95%CI 0.59-0.64),校准图显示风险被低估。
- 最终更新模型移除预测因子「肝硬化伴门脉高压」并加入「多重用药」,区分度提升至C统计量0.64(95%CI 0.59-0.70),校准图改善,总体准确度保持良好。
临床怎么用
- 对老年住院患者出院前可使用更新后的OPERAM DRA预测模型评估药物相关再入院风险。
- 模型区分度仅为中等,临床应用时需结合其他临床信息综合判断。
局限性
- 更新模型区分度仍为中等(C统计量0.64,95%CI 0.59-0.70),尚需进一步开发性能更优的模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Drug-related readmissions (DRAs) are defined as rehospitalizations with an adverse drug event as their main or significant contributory cause. DRAs represent a major adverse health burden for older patients. A prediction model which identified older hospitalized patients at high risk of a DRA <1 year was previously developed using the OPERAM trial cohort, a European cluster randomized controlled trial including older hospitalized patients with multimorbidity and polypharmacy. This study has performed external validation and updated the prediction model consequently. METHODS: The MedBridge trial cohort (a multicenter cluster randomized crossover trial performed in Sweden) was used as a validation cohort. It consisted of 2516 hospitalized patients aged ≥65 years. Model performance was assessed by: (1) discriminative power, assessed by the C-statistic with a 95% confidence interval (CI); (2) calibration, assessed by visual examination of the calibration plot and use of the Hosmer-Lemeshow goodness-of-fit test; and (3) overall accuracy, assessed by the scaled Brier score. Several updating methods were carried out to improve model performance. RESULTS: In total, 2516 older patients were included in the validation cohort, of whom 582 (23.1%) experienced a DRA <1 year. In the validation cohort, the original model showed a good overall accuracy (scaled Brier score 0.03), but discrimination was moderate (C-statistic 0.62 [95% CI 0.59-0.64]), and calibration showed underestimation of risks. In the final updated model, the predictor "cirrhosis with portal hypertension" was removed and "polypharmacy" was added. This improved the model's discriminative capability to a C-statistic of 0.64 (95% CI 0.59-0.70) and enhanced calibration plots. Overall accuracy remained good. CONCLUSIONS: The updated OPERAM DRA prediction model may be a useful tool in clinical practice to estimate the risk of DRAs in older hospitalized patients subsequent to discharge. Our efforts lay the groundwork for the future development of models with even better performance.
引用
- Snijders BMG, Kempen TGH, Aubert CE, et al. Drug-related readmissions in older hospitalized adults: External validation and updating of OPERAM DRA prediction tool. J Am Geriatr Soc. 2023. PMID: 37615214. doi:10.1111/jgs.18575
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。